We are excited to announce our continued expansion into Europe by partnering with Source to launch the first Europe-listed ETF to track the Nasdaq Biotechnology Index (NBI), the Source Nasdaq Biotechnology UCITS ETF (SBIO).
The Nasdaq Biotechnology Index (NBI) reflects the performance of over 100 biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market. The 122 constituents range from global giants with diverse portfolios to smaller companies focused on a single treatment.
"Since the Nasdaq Biotechnology Index launched in 1993, it has evolved into a key industry benchmark for tracking the growth and performance of this increasingly important sector," Rob Hughes, Nasdaq head of index and advisor solutions said. "Nasdaq has been home to some of the world's most innovative companies in the Biotech sector and we are proud of our history and partnerships in the space. We are excited to team with another innovator, Source, who will introduce the Nasdaq Biotech Index to a European audience for the first time."
The Source Nasdaq Biotechnology UCITS ETF is denominated in USD and will trade on both the London Stock Exchange and the SIX Swiss Exchange. It is also registered for sale in Austria, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands and Norway.
To learn more about the Nasdaq Biotechnology Index, please visit the NBI Overview page.